CEA-negative glioblastoma and melanoma cells are sensitive to cytosine deaminase/5-fluorocytosine therapy directed by the carcinoembryonic antigen promoter.
Dabrowska
Anna
A
Department og Immunochemistry, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Szary
Jarosław
J
Kowalczuk
Małgorzata
M
Szala
Stanisław
S
Ugorski
Maciej
M
D001483:Base Sequence; D002272:Carcinoembryonic Antigen / Q000235:genetics / Q000378:metabolism*; D045744:Cell Line, Tumor; D043525:Cytosine Deaminase / Q000235:genetics* / Q000378:metabolism; D018076:DNA, Complementary / Q000235:genetics; D004273:DNA, Neoplasm / Q000235:genetics; D004926:Escherichia coli / Q000201:enzymology / Q000235:genetics; D005437:Flucytosine / Q000627:therapeutic use*; D015316:Genetic Therapy; D005909:Glioblastoma / Q000235:genetics / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D008545:Melanoma / Q000235:genetics / Q000276:immunology* / Q000628:therapy*; D011355:Prodrugs / Q000627:therapeutic use*; D011401:Promoter Regions, Genetic; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014162:Transfection
D002272:Carcinoembryonic Antigen; D018076:DNA, Complementary; D004273:DNA, Neoplasm; D011355:Prodrugs; D005437:Flucytosine; D043525:Cytosine Deaminase